Stock CRMD CORMEDIX INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus CorMedix Inc.

Equities

CRMD

US21900C3088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
5.28 USD -2.58% Intraday chart for CorMedix Inc. -9.59% +40.43%
Apr. 15 CorMedix's DefenCath Now Commercially Available For US Inpatient Use MT
Apr. 15 CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin) CI

Evolution of the average Target Price on CorMedix Inc.

Price target over the last 5 years

History of analyst recommendation changes

3f.gZ4sUEhsG7RxM7IYKNqUHTp9rHtGfl7uyIhaUpwGvlU.uMt0Hn48L4UEaughcrnBT3tE-EgDGAimicdqINdV02SzqGRgAl8i8RwHwQ~66a6ef644815690f19dfc9d1d54d26d2

Analyst Recommendations on CorMedix Inc.

RBC Trims Price Target on CorMedix to $9 From $10, Keeps Outperform Rating, Speculative Risk Qualifier MT
RBC Boosts Price Target on CorMedix to $10 From $6 on 'Heightening Prospects of DefenCath Reaching Market,' Keeps Outperform, Speculative Risk MT
RBC Initiates CorMedix at Outperform, Speculative Risk With $6 Price Target, Sees DefenCath 'More Likely Than Not to Be Approved' MT
JMP Securities Adjusts Price Target on CorMedix to $19 From $16, Keeps Market Outperform Rating MT
JMP Securities Adjusts CorMedix's Price Target to $16 From $14, Keeps Market Perform Rating MT
Truist Securities Lowers CorMedix's Price Target to $16 From $27, Maintains Buy Rating MT
JMP Securities Adjusts CorMedix Price Target to $14 From $19, Maintains Market Outperform Rating MT
Needham Adjusts CorMedix's Price Target to $12 from $20, Keeps Buy Rating MT
CORMEDIX : Needham & Co Adjusts CorMedix PT to $29 From $31, Maintains Buy Rating MT
CORMEDIX : B. Riley Lowers CorMedix' Price Target to $13.50 from $25 After FDA Rejects DefenCath Due to Manufacturing Issues, Keeps Buy Rating MT
CORMEDIX : Needham Starts CorMedix at Buy With $31 Price Target MT
CORMEDIX : B. Riley Adjusts CorMedix' Price Target to $25 From $11, Keeps Buy Rating MT
CORMEDIX : Truist Securities Adjusts CorMedix PT to $35 From $20, Maintains Buy Rating MT
CORMEDIX : Truist Securities Adjusts CorMedix' Price Target to $35 from $20, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.28 USD
Average target price
13 USD
Spread / Average Target
+146.21%
High Price Target
19 USD
Spread / Highest target
+259.85%
Low Price Target
9 USD
Spread / Lowest Target
+70.45%

Consensus detail

Consensus revision (last 18 months)

Analysts covering CorMedix Inc.

RBC Capital Markets
JMP Securities
Truist Securities
Needham & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CRMD Stock
  4. Consensus CorMedix Inc.